REGN - Spark Newswire

2 minute read

Jim Cramer Says He’s ‘Still Feeling Good’ About These 5 Stocks From ‘Mutilated’ Nasdaq

Today, 5:55 AM

Prominent market commentator Jim Cramer has recommended five stocks from the Nasdaq Index that he believes could be decent additions to investors’ portfolios.

AEP

1 minute read

Sensei Biotherapeutics Announces Clinical Supply Agreement With Regeneron For Phase 1/2 Clinical Trial Evaluating SNS-101, A Conditionally Active VISTA-Blocking Antibody, in Combination With Libtayo Ij Solid Tumors

By Benzinga Newsdesk

Today, 5:55 AM

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced a clinical supply agreement with Regeneron for

REGN

5 minute read

Biogen’s 2nd Alzheimer’s Antibody, BeiGene’s Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors

By Shanthi Rexaline

Today, 5:55 AM

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

BGNE

1 minute read

Regeneron-Sanofi’s Dupixent Wins European Approval For Prurigo Nodularis

By Vandana Singh

Today, 5:55 AM

The European Commission (EC) has expanded the marketing authorization of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for moderate-to-severe prurigo…

REGN

3 minute read

Regeneron Pharmaceuticals Says Odronextamab (CD20xCD3) Demonstrates High, Durable Complete Response Rate Among Patients With Relapsed/Refractory Follicular Lymphoma In Phase 2 Trial

By Michael Horton

Today, 5:55 AM

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive first data from a cohort of a pivotal Phase 2 trial evaluating investigational odronextamab in patients with heavily pre-treated, relapsed/refractory

REGN

5 minute read

Regeneron Pharmaceuticals, Linvoseltamab Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses In Patients With Heavily Pre-Treated Multiple Myeloma

By Benzinga Newsdesk

Today, 5:55 AM

As presented at ASH, recommended 200 mg dose of linvoseltamab demonstrated a 64% response rate, with 45% of responders achieving a very good partial response or better; responses may further improve

REGN

3 minute read

Events
News

Regeneron Pharmaceuticals Announced Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH 2022

By Charles Gross

Today, 5:55 AM

- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new and updated data from a Phase 1 and pivotal Phase 2 trial (ELM-1 and ELM-2) evaluating investigational odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

REGN

1 minute read

Regeneron’s Evkeeza Under FDA Priority Review For Younger Kids With Inherited Form Of High Cholesterol

By Vandana Singh

Today, 5:55 AM

The FDA has accepted Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) supplemental marketing application seeking approval for Evkeeza (evinacumab-dgnb) as an adjunct to other…

REGN

1 minute read

Cramer On This Stock Down 65% Year-To-Date: ‘I Do Believe It’s Bottoming, But I Don’t Know What Gets It Higher’

By Lisa Levin

Today, 5:55 AM

On CNBC’s "Mad Money Lightning Round," Jim Cramer said BioXcel Therapeutics Inc (NASDAQ: BTAI) "may be home run or nothing, and that’s always tough."

BTAI

1 minute read

$100 Invested In This Stock 15 Years Ago Would Be Worth $4,000 Today

By Benzinga Insights

Today, 5:55 AM

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 21.17% on an annualized basis producing an average annual return of 27.88%. Currently, Regeneron Pharmaceuticals has a market capitalization of $80.91 billion.

REGN

Feed Symbols: REGN